Can Antidepressants Make BPD Worse?

Antidepressants can worsen specific symptoms of borderline personality disorder, including suicidal behavior and emotional numbness, and meta-analyses consistently find little evidence that they improve the core features of BPD itself. That does not mean they are always harmful for someone with this diagnosis, but the relationship between antidepressants and BPD is far more fraught than many patients realize. The reality involves misdiagnosis, polypharmacy, and a mismatch between what antidepressants are designed to do and what BPD actually involves at a neurobiological level.

What Meta-Analyses Actually Show

The broadest evidence reviews paint a discouraging picture for antidepressant use in BPD when it is not accompanied by a clear episode of major depression. A meta-analytic review found that antidepressants provided little evidence of benefit for BPD outside of co-occurring major depressive episodes.¹ A separate Cochrane review concluded that antidepressants had no significant effects on overall BPD severity, no meaningful impact on impulsivity, and no benefits for suicidal behaviors. The review went further: fluoxetine was associated with a worsening of suicidal ideation. Among the antidepressants studied, only amitriptyline, an older tricyclic, showed a significant effect on depression in BPD patients. Affective instability was slightly improved by fluvoxamine, but other core symptoms like self-harm, chronic emptiness, and anger did not budge.²

Another meta-analysis compared antidepressants against mood stabilizers and antipsychotics specifically for depression and anger in BPD. Antidepressants had only a small effect size for depression, which is striking given that treating depression is supposed to be their primary job. They showed a moderate effect on anger, but mood stabilizers outperformed them substantially on that front, with a large pooled effect size for anger reduction.³ When the best available evidence says these drugs barely move the needle on the condition they are most prescribed for, you have a genuine problem.

The Suicide and Self-Harm Risk

The most alarming finding involves suicidal behavior. A large comparative effectiveness study published in JAMA Network Open found that antidepressant treatment was associated with a roughly one-third increase in the risk of attempted or completed suicide among people with BPD. The hazard ratio was 1.33, meaning the risk was 33% higher during periods of antidepressant use compared to periods without. Benzodiazepines performed even worse, with a 62% increase. Antipsychotics sat in between at a 22% increase. These associations held up even after the researchers removed the first 30 or 60 days of each medication exposure period from the analysis, a step designed to rule out the possibility that the drugs were simply being started during crisis moments that already carried high risk.⁴

This is an observational study, so it cannot prove that antidepressants directly cause the increased risk. People who receive antidepressants may be sicker to begin with, or they may be dealing with additional stressors that prompted the prescription. But the sensitivity analyses, which stripped out the early high-risk window, make simple confounding harder to wave away. And the Cochrane review’s finding that fluoxetine specifically worsened suicidal ideation adds a mechanistic thread to the statistical pattern.²

Emotional Blunting and the BPD Experience

One way antidepressants can feel worse-than-useless for BPD patients involves emotional blunting. SSRIs and SNRIs reduce the ability to experience emotions across the board, both positive and negative. Roughly 40 to 60 percent of people on these medications report some degree of this effect. Patients describe feeling emotionally numb, detached from relationships, and unable to have genuine emotional reactions to situations that would normally provoke them. Some report feeling like observers of their own lives rather than participants.⁵

For people with BPD, this effect can collide badly with existing symptoms. Chronic feelings of emptiness are already a hallmark of the condition. Adding pharmaceutical emotional dampening on top of that can intensify the sense of disconnection and hollowness that BPD patients already struggle with. The irony is that one of the few areas where some antidepressants show modest benefit in BPD is affective instability, the rapid mood shifts. But the mechanism that dampens those shifts does not selectively target the painful emotions; it flattens everything. For someone whose emotional life is already fractured, losing access to positive emotions while the painful ones are only partially muted is not an obvious improvement. Many patients report fundamental changes in their personality, including loss of their characteristic emotional responses, which in BPD can feel like losing the only thing that makes you feel alive.

Why Antidepressants Are Prescribed So Often Anyway

Given the lackluster evidence, the prescribing rates for antidepressants in BPD are remarkable. A study using New Zealand’s national databases found that among people with a BPD diagnosis who received any psychotropic medication, about 77% were dispensed antidepressants in 2014, rising to just over 80% by 2019.⁶ Four out of five medicated BPD patients on antidepressants, for a condition where the best evidence says these drugs do not improve the core syndrome.

Several factors drive this. The most straightforward is comorbidity. BPD rarely travels alone. Depression, anxiety disorders, PTSD, and eating disorders frequently co-occur, and antidepressants are first-line treatments for several of those conditions. When a clinician is treating someone with BPD and co-occurring major depression, prescribing an antidepressant for the depression is reasonable. The complication is that patients with psychiatric comorbidities tend to respond worse to antidepressants than patients with depression alone. A meta-analysis found that antidepressant outcomes were significantly poorer when co-occurring psychiatric conditions were present.⁷ So the antidepressant may help the depression component, but less so than it would for someone without BPD complicating the picture.

Misdiagnosis also plays a role. BPD is frequently confused with bipolar disorder, which shares surface-level features like mood instability and impulsive behavior. In one study, nearly 40% of patients who met criteria for BPD reported having previously been misdiagnosed with bipolar disorder, compared to about 10% of patients without BPD.⁸ A patient misdiagnosed with bipolar depression might receive antidepressants (along with mood stabilizers) under a treatment framework that simply does not match their actual condition. Years can pass before the correct diagnosis is established, during which the patient is treated for a disorder they do not have.

The Polypharmacy Spiral

Antidepressant prescribing in BPD does not usually happen in isolation. More than half of patients with the diagnosis end up on three or more psychotropic medications, a pattern called polypharmacy.⁹ The New Zealand database study found that about half of medicated BPD patients were on three or more medications in 2014, rising to nearly 56% by 2019. Some individuals were dispensed as many as 15 to 18 different psychotropic medications.⁶

This escalation often follows a predictable pattern. An antidepressant is prescribed, produces limited or mixed results, and rather than discontinuing it, a second medication is added to address a different symptom cluster or to manage side effects of the first. Over time, the patient accumulates a cocktail of drugs, each added for a rational-sounding reason, none of which was tested in combination with the others for this specific condition. The risks of this kind of layering are poorly studied in BPD populations, but the general pharmacology is clear: more drugs mean more interactions, more side effects, and a harder time figuring out which medication is doing what. Notably, most BPD patients end up medicated even when they have no psychiatric comorbidities at all, suggesting that the prescribing is often aimed at BPD symptoms directly despite the weak evidence for doing so.⁹

Why the Serotonin Picture Is More Complicated Than It Looks

The rationale for using SSRIs in BPD rests partly on the observation that serotonin signaling is disrupted in the condition. Reduced serotonin activity in the prefrontal cortex has been linked to the impulsive behavior, aggression, and mood swings typical of BPD.¹⁰ The logic seems intuitive: if serotonin is low and SSRIs raise serotonin, the problem should improve. But the biology is not that tidy.

BPD involves dysfunction across multiple brain systems simultaneously. The amygdala, which processes emotional threat, tends to be hyperactive. The prefrontal cortex, which is supposed to regulate the amygdala’s alarm signals, is underactive. Serotonin modulates both systems, but boosting serotonin with an SSRI does not surgically correct the imbalance between them. The response varies dramatically between individuals, as the neurobiological review notes.¹⁰ Some people may experience partial relief from impulsivity; others may feel no change or get worse. This is not the kind of condition where a single neurotransmitter adjustment fixes the underlying circuit problems.

Fluvoxamine, for instance, produced a lasting reduction in rapid mood shifts in one randomized controlled trial of women with BPD, but had no effect whatsoever on impulsivity or aggression.¹¹ That selective profile tells you something important: these drugs can tweak one dimension of the BPD experience while leaving others completely untouched. When a prescriber and patient are hoping for broad improvement across emotional instability, impulsivity, interpersonal chaos, and chronic emptiness, a medication that only nudges one piece of that puzzle feels like a disappointment at best.

When Antidepressants Might Still Be Worth Trying

None of this means antidepressants should be categorically avoided in everyone with BPD. The clearest case for their use is when a patient has a genuine co-occurring episode of major depression on top of their personality disorder. Depression is common in BPD but distinct from the chronic emptiness and emotional pain that characterize the condition itself. When a discrete depressive episode meets full diagnostic criteria, antidepressants can help with that specific component, even though the BPD symptoms may not improve.¹ The key is being honest about what the medication is targeting and what it is not.

Anxiety disorders, PTSD, and obsessive-compulsive symptoms also frequently co-occur with BPD, and antidepressants have an established evidence base for those conditions. A patient whose daily functioning is severely impaired by panic attacks or intrusive OCD thoughts may benefit from an SSRI even if their BPD symptoms remain unchanged. The trouble starts when the antidepressant is prescribed for BPD itself, with the hope that it will address the emotional dysregulation, unstable relationships, and identity disturbance that define the condition. For those targets, the evidence simply is not there.

What Works Better for Core BPD Symptoms

The strongest evidence for treating BPD itself belongs to psychotherapy, not pharmacotherapy. Dialectical behavior therapy, or DBT, was developed specifically for BPD and has the most robust research support. It targets emotional regulation, distress tolerance, and interpersonal skills through structured individual and group sessions. Mentalization-based therapy, schema therapy, and transference-focused psychotherapy also have evidence behind them. These approaches address the psychological mechanisms that drive BPD symptoms in a way that no pill currently can.

On the pharmacology side, mood stabilizers showed more promise than antidepressants in meta-analytic comparisons for anger, one of the more disruptive BPD symptoms. The pooled effect size for mood stabilizers on anger was large, dwarfing the moderate effect seen with antidepressants.³ That said, no class of medication has demonstrated broad, consistent improvement across the full range of BPD symptoms. The current thinking in evidence-based treatment is that medication should play a supporting role, targeting specific symptoms or comorbid conditions, while psychotherapy does the heavy lifting on the disorder itself.

The Cost of Getting It Wrong

Ineffective or harmful prescribing in BPD is not just a clinical concern. It carries real economic weight. A comprehensive evaluation of the societal burden of BPD found that average total societal costs for someone with BPD were roughly €35,000 per person, nearly six times higher than for people without severe psychological complaints. The overwhelming majority of those costs, about 91%, were attributed to psychological problems. Healthcare spending was significantly higher across psychiatric outpatient treatment, general practitioner visits, emergency care, social work, and medication.¹²

When patients cycle through antidepressant after antidepressant, accumulate polypharmacy regimens, visit emergency departments during crises that medications failed to prevent, and delay access to the psychotherapy that has the best evidence, those costs pile up. The medications themselves are relatively cheap. The downstream consequences of relying on them as a primary treatment for a condition they were not designed to treat are not. Every year spent on an ineffective medication regimen is a year not spent in structured psychotherapy, and BPD is a condition where evidence-based therapy can produce meaningful, lasting improvement in a way that antidepressants, for most patients, cannot.

What to Ask Your Prescriber

If you have BPD and are currently taking or being offered an antidepressant, a few questions are worth raising. First, what specific symptom is this medication targeting? If the answer is “your BPD” in a general sense, the evidence does not support that use. If the answer is a co-occurring condition like major depression, anxiety, or PTSD, the rationale is on firmer ground. Second, how will you know if it is working? Without a clear target and a timeline for evaluating response, you can end up staying on a drug indefinitely out of inertia. Third, are you on other psychotropic medications, and has anyone reviewed whether the full combination makes sense? Given that more than half of medicated BPD patients end up on three or more drugs, this question is not hypothetical.⁶

Finally, if you are not in evidence-based psychotherapy, that should be the priority. Medication adjustments feel easier and faster than committing to weekly therapy sessions, and in the short term they are. But for a condition where the strongest treatments are psychological, optimizing your medication while skipping therapy is working on the wrong problem. That is not a knock on anyone who has found an antidepressant genuinely helpful for a co-occurring condition. It is a recognition that BPD, as a disorder, does not respond to antidepressants the way depression does, and treating it as though it should can make the path to recovery longer and more painful than it needs to be.

1
Europe PMC. Borderline personality disorder: current drug treatments and future prospects.
2
Annals of General Psychiatry. Treating depression in patients with borderline personality disorder: clinical clues on the use of antidepressants
3
PubMed. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms
4
JAMA Network Open. Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
5
Psychopharmacology Institute. Antidepressant-Induced Emotional Blunting: Diagnosis, Mechanisms and Management
6
PMC. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand’s national databases
7
Elsevier. Antidepressant treatment outcomes in patients with and without comorbid physical or psychiatric disorders: A systematic review and meta-analysis
8
Journal of Psychiatric Research. Borderline Personality Disorder and the Misdiagnosis of Bipolar Disorder
9
SpringerOpen. Pharmacological Management of Borderline Personality Disorder and Common Comorbidities
10
PMC. Understanding the Borderline Brain: A Review of Neurobiological Findings in Borderline Personality Disorder (BPD)
11
American Journal of Psychiatry. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder
12
Wiley Online Library. Burden of Disease of Borderline Personality Disorder: A Comprehensive Evaluation of Quality of Life and Societal Cost of Illness